# The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction

Study · id `cardio:ct-nct05043558` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05043558](<https://clinicaltrials.gov/study/NCT05043558>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05043558

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 220 participants.

## Technical summary

Registry record NCT05043558. Randomized; single masking; primary purpose treatment. Start 2022-01-01 (anticipated); primary completion 2022-01-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT05043558, source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)
- Planned start: 2022-01-01 (anticipated) (ClinicalTrials.gov record NCT05043558, source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)
- Primary completion: 2022-01-10 (anticipated) (ClinicalTrials.gov record NCT05043558, source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)
- Completion: 2022-01-12 (anticipated) (ClinicalTrials.gov record NCT05043558, source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05043558, source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05043558-2021-09-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction
- Condition: STEMI
- Intervention (Drug): beprostaglandin sodium
- Lead sponsor: Shenzhen People's Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: ce755c9ecabaa059556f83c4a08f991f7a66e711e5688cc5ada9b837eef47bff
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
